PMGC Holdings ELAB
NASDAQ ELAB
$4.70 +0.08 (+1.72%)
As of: Sep 10, 2026 · 12:55 PM EDT

PMGC Holdings (ELAB) Share-based Compensation (2022 - 2026)

PMGC Holdings' (ELAB) quarterly Share-based Compensation came in at $1.1 million in Q2 2026, up 7005.78% year-over-year from $15842.0 in Q2 2025, and up 142.91% quarter-over-quarter from $463421.0 in Q1 2026.

Analysis

PMGC Holdings (ELAB) Share-based Compensation (2022 - 2026) Analysis & Trends

PMGC Holdings has disclosed Share-based Compensation across 5 years of filings, most recently posting $1.1 million for Q2 2026.

  • In Q2 2026, Share-based Compensation rose 7005.78% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $1.1 million (up 896.63% YoY), while the FY2025 annual figure was $36616.0, down 94.66% from the prior year.
  • Share-based Compensation came in at $1.1 million for Q2 2026 at PMGC Holdings, up from $463421.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $35.6 million in Q3 2022 to a low of -$93.9 million in Q4 2022.
  • Average Share-based Compensation over 5 years is -$3.2 million, with a median of $125548.5 recorded in 2023.
  • Year-over-year, Share-based Compensation tumbled 103.78% in 2025 and soared 7005.78% in 2026.
  • Over 5 years, Share-based Compensation stood at -$93.9 million in 2022, then surged by 100.15% to $141190.0 in 2023, then tumbled by 89.55% to $14756.0 in 2024, then surged by 350.21% to $66433.0 in 2025, then soared by 1594.49% to $1.1 million in 2026.
  • Per Business Quant data, the three most recent Share-based Compensation figures were $1.1 million in Q2 2026, $463421.0 in Q1 2026, and $66433.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Amgen 206.40 Bn 192.42 Bn 7.24 Bn 247.00 Mn
2 Gilead Sciences 180.38 Bn 177.20 Bn 6.22 Bn 231.00 Mn
3 Vertex Pharmaceuticals 131.28 Bn 123.43 Bn 2.84 Bn 108.10 Mn
4 Regeneron Pharmaceuticals 81.73 Bn 73.73 Bn 3.93 Bn 243.00 Mn
5 Argenx Se 60.28 Bn 55.09 Bn 1.37 Bn -
6 Moderna 54.02 Bn 48.88 Bn 52.00 Mn 120.00 Mn
7 Alnylam Pharmaceuticals 33.28 Bn 29.97 Bn 992.69 Mn 86.63 Mn
8 Biogen 31.81 Bn 30.52 Bn 1.96 Bn 77.40 Mn
9 Roivant Sciences 29.02 Bn 29.02 Bn 1.16 Mn 83.34 Mn
10 PMGC Holdings 2.29 Mn -16.50 Mn 385,691.00 1.13 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.13 Mn
Mar 31, 2026 463,421.00
Dec 31, 2025 66,433.00
Sep 30, 2025 13,180.00
Jun 30, 2025 15,842.00
Mar 31, 2025 -58,838.00
Dec 31, 2024 14,756.00
Sep 30, 2024 1.22 Mn
Jun 30, 2024 1.35 Mn
Mar 31, 2024 1.56 Mn
Dec 31, 2023 141,190.00
Sep 30, 2023 1.54 Mn
Jun 30, 2023 109,907.00
Mar 31, 2023 75,161.00
Dec 31, 2022 -93.93 Mn
Sep 30, 2022 35.59 Mn